Deazapurines useful as inhibitors of Janus kinases
The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The compounds are generally represented by structural formula I or pharmaceutically acceptable salts thereof:
1. A compound selected from any one of the following structural formulae or a pharmaceutically acceptable salt thereof:
2. A compound selected from any one of the following structural formulae or a pharmaceutically acceptable salt thereof:
3. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
4. The composition according to claim 3 , additionally comprising a therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorders, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.
5. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
6. A pharmaceutical composition comprising a compound according to claim 2 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.